09:48 AM EST - ProMIS Neurosciences, Inc. : Announced today that the Alzheimer’s Association International Conference® (AAIC®) has accepted several abstracts for the company’s Alzheimer’s disease (AD) program. The AAIC also invited ProMIS Chief Development Officer Dr. Johanne Kaplan to chair a session on novel immunotherapeutic approaches for the treatment of AD. AAIC 2020 is currently scheduled for July 26-30 in Amsterdam. ProMIS Neurosciences, Inc.
shares T.PMN are trading unchanged at $0.13.
